Inter-individual variance in 6-mercaptopurine (6-MP) dose intensity is common in patients with acute lymphoblastic leukemia (ALL). We aimed to evaluate the association of common variants of , , , and with 6-MP dose intensity and toxicity in pediatric ALL patients. In this cohort, 13.8% of patients were intolerant to 6-MP with actual dosage less than 50% of scheduled dose. Twenty percent of patients were found to be heterozygous or homozygous mutated with . c.415C > T and the genotype-predicted NUDT15 activity were significantly associated with 6-MP intolerance. *3C variants were not common in this cohort (2.8%). polymorphisms and genotype predicted NUDT15 activity were significantly associated with 6-MP dose intensity and leukopenia episodes. Combination of and variants ( c.912G > T and c.94C > A) also showed significant positive association with 6-MP intolerance in Chinese children with ALL. Further study on pharmacogenetic screening for ALL patients to avoid 6-MP induced toxicity is recommended.Supplemental data for this article is available online at https://doi.org/10.1080/08880018.2021.1973628.
Download full-text PDF |
Source |
---|---|
http://dx.doi.org/10.1080/08880018.2021.1973628 | DOI Listing |
Enter search terms and have AI summaries delivered each week - change queries or unsubscribe any time!